Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 13, 2019

SELL
$7.67 - $10.63 $383,500 - $531,500
-50,000 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$7.58 - $9.94 $265,300 - $347,900
35,000 Added 233.33%
50,000 $497,000
Q4 2018

Feb 12, 2019

BUY
$7.16 - $16.21 $28,640 - $64,840
4,000 Added 36.36%
15,000 $115,000
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $106,699 - $216,149
11,000 New
11,000 $192,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.28B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Myda Advisors LLC Portfolio

Follow Myda Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Myda Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Myda Advisors LLC with notifications on news.